1. Introduction {#sec1}
===============

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease and a major risk factor for cardiovascular disease \[[@B1], [@B2]\]. Patients with DN have a higher risk of mortality, mainly due to cardiovascular complications, in comparison with diabetic patients without nephropathy \[[@B2]\]. As the number of patients with type 2 diabetes mellitus (T2DM) with end-stage renal disease has increased significantly over the past two decades, more research is required to discover new approaches to prevent or slow this worsening of renal function. Genetic susceptibility seems important in the pathogenesis of DN according to variable incidence rates of DN between different ethnic groups, aggregation of DN and diabetic end-stage renal disease in families, and high heritability estimates for diabetic renal histologic alterations, glomerular filtration rate, and albuminuria \[[@B3]\]. Identification of genes implicated in the basic mechanisms contributing to onset and advancement of DN is crucial for developing novel preventive and therapeutic strategies.

Inflammatory processes play a central role in the development and progression of DN. Inflammation is characterized by leukocyte infiltration at every stage of renal involvement and by increased expression of adhesion molecules, chemokines, and proinflammatory cytokines \[[@B1]\]. Increased levels of cell adhesion molecules in T2DM were shown to be strongly associated with both DN and cardiovascular disease complications and mortality \[[@B4]\].

Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a multifunctional vascular cell adhesion molecule and signaling molecule of the immunoglobulin (Ig) superfamily that is expressed on the surface of circulating leukocytes and platelets. PECAM-1 is also highly expressed on endothelial cells, where it is an important component of endothelial cell intercellular junctions in vascular beds \[[@B5]\]. The 130 kDa glycoprotein entails a single-chain molecule of six Ig-like extracellular homology domains, a 19-residue transmembrane portion, and a 118-residue cytoplasmic tail \[[@B6]\]. The extracellular domain of PECAM-1 mediates homo- and heterophilic interactions, which can occur via the first N-terminal Ig homology domain, while the cytoplasmic region is involved in the transduction of various cellular signals \[[@B7]\].

As a signaling adhesion molecule, PECAM-1 serves various proinflammatory and anti-inflammatory functions and thus plays a crucial role in the regulation of vascular inflammatory response \[[@B8]\]. Proinflammatory functions of PECAM-1 comprise the facilitation of leukocyte transendothelial migration and the transduction of mechanical signals in endothelial cells originating from fluid shear stress, whereas PECAM-1 anti-inflammatory effects include the dampening of leukocyte activation, suppression of proinflammatory cytokine production, and the maintenance and restoration of vascular barrier integrity \[[@B8]\]. PECAM-1 homophilic interactions, which occur through its first extracellular domain, are required for leukocyte transmigration \[[@B9]\] and have an important role in interendothelial cell bindings and regulation of vascular permeability \[[@B5]\].

PECAM-1 is encoded by a 75 kb gene that is located near the end of the long arm of chromosome 17 (17q23) and comprises 16 exons \[[@B10]\]. The rs668 polymorphism (C373G) in exon 3 of*PECAM-1* gene at codon 125 causes a mutation of leucine to valine (Leu125Val). The Leu125Val polymorphism has been shown to be related to coronary artery disease \[[@B11]--[@B13]\], ischemic stroke \[[@B14]\], atherosclerotic cerebral infarction \[[@B15]\], bronchial asthma \[[@B16]\], deep vein thrombosis \[[@B17]\], and sepsis \[[@B18]\]. However, the results of the association genetic studies published so far have not been unequivocal \[[@B19], [@B20]\].

Notably, our study group was earlier able to confirm an association between Leu125Val polymorphism and myocardial infarction in subjects with T2DM \[[@B21]\]. As patients with DN have a substantially increased risk of developing cardiovascular complications, we hypothesized that PECAM-1 may be an important factor involved in both micro- and macrovascular pathogenesis of T2DM. Therefore, we investigated the relationship between the Leu125Val polymorphism (rs668) in*PECAM-1* gene and DN in subjects with T2DM. We also tested the association between the aforementioned polymorphism and the serum concentration of sPECAM-1 in a subpopulation of T2DM subjects with DN.

2. Patients and Methods {#sec2}
=======================

In this cross-sectional case-control study we enrolled 651 unrelated Caucasians with T2DM of more than 10 years duration from outpatient clinics of the University Medical Centre Maribor and General Hospitals, Murska Sobota and Slovenj Gradec. The study group consisted of 276 subjects with DN (cases) and 375 subjects without clinical signs of DN (control group). Patients were classified as having T2DM according to the current American Diabetes Association criteria \[[@B22]\]. Diagnosis of DN was made according to WHO (World Health Organization) 1999 diagnostic criteria \[[@B23]\].

To avoid the confounding effect of impaired kidney function, patients with overt nephropathy were not enrolled in the study. Patients with poor glycaemic control, significant heart failure (NYHA II--IV), alcoholism, infection, and other causes of renal disease were also excluded. The study was approved by the national medical ethics committee and was performed in compliance with the Helsinki Declaration. After an informed consent for the participation in the study was obtained, a detailed interview was conducted. Information on smoking, presence, and family history of cardiovascular disease, duration of arterial hypertension and T2DM, T2DM management and complications (retinopathy, neuropathy, and diabetic foot), therapy, and routine laboratory measurements were obtained from their medical records.

2.1. Biochemical Analyses {#sec2.1}
-------------------------

Total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides, cystatin C, fasting glucose, glycated hemoglobin (HbA1c), urea, and creatinine were determined by standard biochemical methods. For each patient, albumin to creatinine ratio was determined in three urine samples, according to diagnostic criteria. Cystatin C and MDRD study equation were used to estimate glomerular filtration rate (eGFR).

2.2. Determination of sPECAM-1 Level {#sec2.2}
------------------------------------

Level of plasma soluble PECAM-1 (sPECAM-1) was measured by ELISA in a subpopulation of 120 diabetics with DN.

2.3. Genotyping {#sec2.3}
---------------

After the genomic DNA was extracted with FlexiGene DNA isolation kit (Qiagen GmbH, Hilden, Germany) polymorphism C373G (rs668) of PECAM-1 gene was genotyped with KASP genotyping chemistry in UK (KBioscience Limited, acquired by LGC Genomics; Acquirer Information: LGC Genomics Ltd., Unit 1-2 Trident Industrial Estate, Hoddesdon, Hertfordshire, United Kingdom) according to standard protocol as follows: hot-start activation 94°C for 15 minutes, 10 cycles at 94°C for 20 seconds, at 61--55°C for 60 seconds, and 26 cycles at 94°C for 20 seconds and at 55°C for 60 seconds.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was performed using the SPSS program for Windows version 19 (SPSS Inc., Illinois). Continuous clinical data were compared by unpaired Student\'s *t*-test, while chi-square test was used to compare discrete variables and genotype distributions. Data were presented as mean ± SD (continuous variables) or as the number and percent of patients (categorical variables). Further, all variables that showed significant differences by univariate analysis (with a *p* value \< 0.05 considered significant) were analyzed together in a logistic regression analysis. A *p* \< 0.05 was considered statistically significant. The deviation from Hardy-Weinberg equilibrium (HWE) was assessed by the exact test (<https://ihg.gsf.de/> ).

3. Results {#sec3}
==========

The demographic and clinical characteristics of the cases and control subjects are listed in [Table 1](#tab1){ref-type="table"}. There were no significant differences between groups with respect to age, sex, duration of T2DM, diastolic blood pressure, body mass index (BMI), smoking status, family history of cardiovascular disease (CVD), duration of diabetic retinopathy (DR), estimated glomerular filtration rate (eGFR), serum hemoglobin (Hb), total cholesterol, HDL, and LDL cholesterol levels. On the other hand, statistically significant differences were observed in the following parameters: duration of hypertension, systolic blood pressure, presence of cardiovascular disease (CVD), urine albumin to creatinine ratio, as well as serum fasting glucose, HbA1c, urea, creatinine, and triglyceride (TG) levels. Cases also showed significantly more chronic diabetic complications, such as diabetic retinopathy (DR) and diabetic foot (DF), but not diabetic neuropathy (DNeur).

Differences in parameters reflecting renal function (serum creatinine, cystatin C, eGFR, and urine albumin to creatinine ratio) confirmed chronic kidney disease in diabetic subjects with DN. Cystatin C was a better marker for estimation of renal function than eGFR (MDRD equation ml/min). Cystatin C was significantly higher in subjects with DN (*p* \< 0,001) ([Table 1](#tab1){ref-type="table"}).

The genotype distribution and allele frequencies of Leu125Val polymorphism in subjects with DN (cases) and those without DN (controls) are presented in [Table 2](#tab2){ref-type="table"}. Univariate analysis did not reveal significant differences in the genotype or allele frequencies between TD2M cases and controls ([Table 2](#tab2){ref-type="table"}). The genotype distribution did not significantly deviate from a Hardy-Weinberg equilibrium ([Table 2](#tab2){ref-type="table"}). Logistic regression analysis adjusted for different confounders did not reveal significant effect of the Leu125Val polymorphism on DN risk in subjects with T2DM ([Table 3](#tab3){ref-type="table"}).

No association was found between the Leu125Val polymorphism and serum sPECAM-1 levels in a subpopulation of 120 diabetics with DN ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

In the present case-control study that included 651 Caucasian subjects with T2DM, we failed to confirm an association between the rs688 single nucleotide polymorphism of*PECAM-1* gene (Leu125Val) and DN. Likewise, no association was found between the Leu125Val polymorphism and serum sPECAM-1 levels in a subpopulation of 120 diabetics with DN.

DN is considered an inflammatory disease. Inflammatory cells are implicated at every stage of renal impairment and the extent of inflammatory cell accumulation in the kidney is closely related to DN \[[@B1]\]. A 130 kDa adhesion molecule PECAM-1 is a crucial mediator of leukocyte migration through intercellular junctions of vascular endothelial cells \[[@B5]\] and may thus contribute to micro- and macrovascular inflammatory complications of T2DM. Hyperglycemia and oxidative stress have been shown to promote transendothelial migration of monocytes through phosphorylation of PECAM-1 \[[@B24], [@B25]\], whereas hyperinsulinaemia enhanced neutrophil transendothelial migration by increasing endothelial PECAM-1 expression via mitogen-activated protein kinase activation \[[@B26]\]. Abnormal angiogenesis may also play a significant role in the pathogenesis of DN \[[@B27]\]. PECAM-1 is involved in endothelial cell-cell and cell-matrix interactions and signal transduction, which are essential during angiogenesis \[[@B28]\]. Further, Kondo et al. have demonstrated that PECAM-1 is a critical modulator of endothelial cell adhesion, migration, and capillary morphogenesis in kidneys \[[@B6]\].

In normal kidneys, PECAM-1 is expressed on endothelial cells of glomerular and peritubular capillaries, whereas its expression is reduced in obliterated glomeruli with endothelial cell destruction, such as in diabetic glomerulosclerosis \[[@B29]\]. In animal models with reversible kidney injury, such as anti-Thy1 treatment in rats, PECAM-1 expression increases during the recovery phase \[[@B30]\]. Thus, it seems that, under pathological conditions, compensatory PECAM-1 modulation may enable glomerular endothelial cell survival \[[@B31]\]. Recently, Cheung et al. showed that PECAM-1 signaling is both necessary and sufficient to prevent inflammation-induced endothelial cell death and confer immune privilege to the vascular endothelium \[[@B32]\]. Of interest, Baelde et al. have studied the messenger RNA expression profiles of diabetic glomeruli and*PECAM-1* gene was found to be upregulated among other ninety-six overexpressed genes in comparison to the glomeruli from healthy individuals \[[@B33]\].

PECAM-1/PECAM-1 homophilic interactions, which are mediated by the first NH~2~-terminal Ig homology domain, are primarily responsible for leukocyte transmigration and play a vital role in the regulation of the endothelial barrier function \[[@B5]\]. The first IgG domain of PECAM-1 is encoded by the third exon of*PECAM-1* gene that contains the Leu125Val polymorphism \[[@B10]\]. A single amino acid mutation of leucine to valine may affect the homophilic binding capability and therefore influence PECAM-1-mediated cellular interactions. The Leu125Val (L/V) polymorphism is in strong linkage disequilibrium with amino acid polymorphisms in exon 8 at codon 563 altering a serine to an asparagine (S/N) and in exon 12 at codon 670 altering an arginine to a glycine (R/G) \[[@B10]\]. Goodman et al. have described an association between the LSR and VNG haplotypes and leukocyte/endothelial interaction \[[@B34]\]. Namely, they showed that LSR/VNG heterozygous monocytes adhere better to endothelium under conditions of flow than LSR/VNG homozygous cells \[[@B34]\]. In accordance with the possible functional effect, the Leu125Val polymorphism has been shown to be associated with a number of cardiovascular and cerebrovascular diseases \[[@B11]--[@B15]\] and with sepsis \[[@B18]\].

However, the results of the association genetic studies published so far have not been unequivocal. Similar to our study, Kamiuchi et al. were unable to prove an association between PECAM-1 Val125Leu polymorphism and the presence of diabetic retinopathy in subjects with T2DM \[[@B20]\], whereas Bazzaz et al. found no correlation between PECAM-1 Val125Leu polymorphism and microangiopathic complications in subjects with type 1 diabetes \[[@B35]\]. In Japanese subjects with T2DM, PECAM-1 Val125Leu polymorphism was not associated with chronic kidney disease \[[@B36]\]. However, a possibility of a weak association of PECAM-1 Val125Leu polymorphism with chronic kidney disease was found in Japanese individuals with both T2DM and arterial hypertension \[[@B37]\]. The results from a recent meta-analysis suggested that Leu125Val polymorphism in*PECAM-1* gene is not a susceptibility marker of coronary heart disease \[[@B19]\].

Contrary to our findings, several studies have reported an association between the circulating sPECAM-1 levels and the Leu125Val polymorphism \[[@B12], [@B14], [@B15], [@B17], [@B18]\]. The soluble plasma sPECAM-1 exists in two distinct forms: a transmembraneless 120 kDa form and a truncated 90 kDa form \[[@B38]\]. The transmembraneless sPECAM-1 is formed by alternative splicing of the transmembrane segment-encoding (exon 9) transcript upon cell activation, while the truncated form is generated by PECAM-1 proteolytic cleavage at the cell surface and shedding of the extracellular portion of PECAM-1 into the plasma \[[@B38], [@B39]\]. Soluble forms of PECAM-1 can act as competitive inhibitors of membrane-bound PECAM-1 and by this means regulate the transmigration of leukocytes \[[@B9]\]. It has been suggested that, due to the localization of Leu125Val in the first loop of the extracellular domain of PECAM-1 protein, the leucine to valine mutation may facilitate the cleavage of sPECAM-1 from cell surface and thus increase the serum sPECAM-1 level while decreasing the endothelial barrier function of PECAM-1 \[[@B18]\].

The inconsistencies among the results of our and other genetic association studies may be explained by differences in phenotype definition, the variation in the genetic or environmental background of the populations studied, the possibility of various gene-gene and gene-environment interactions, or insufficient sample size \[[@B40]\]. Although the number of subjects included in our study was relatively small, all the participants were recruited from a rather homogenous genetic and environmental background. In addition, the strength of the study is a rather long duration of T2DM in both cases and control subjects.

T2DM is a multifactorial disease arising from complex interactions between genetic makeup and environmental influences \[[@B41]\]. In order to advance our knowledge of the origin, onset, development, prevention, and treatment of T2DM, besides genetics, we will need to employ epigenomics, transcriptomics, proteomics, and other "omics" in a systematic approach \[[@B41]\]. Further, to unravel the intricate regulatory mechanisms and complex metabolic networks implicated in the pathophysiology of T2DM integrated multiomics methods will have to be applied. Recently, there has been rapid evolution of high-throughput technologies and platforms to assay global DNA, RNA, proteins, and metabolites. All of these "omics" techniques will generate massive amounts of quantitative experimental data, which will require advanced statistical and computational methods and systems biology approaches for successful integration \[[@B42]\]. In addition, the rapid progress of nanotechnology will undoubtedly complement and greatly empower the "omics" fields of medical research \[[@B43]\].

To conclude with, we were not able to prove an association between the Leu125Val polymorphism of the PECAM-1 gene and DN in subjects with T2DM, indicating that rs688 single nucleotide polymorphism is not a genetic marker for susceptibility to DN in Caucasians with T2DM.
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###### 

Clinical and laboratory characteristics of cases and controls.

                                                       Cases (DN+)           Controls (DN−)        Sig. (*p*)
  ---------------------------------------------------- --------------------- --------------------- --------------------
  Number                                               276                   375                    
  Sex (M)                                              59.1%                 52.4%                 0.1
  Age (years)                                          64.75 ± 9.15          63.75 ± 8.0           0.13
  Duration of T2D (years)                              14.71 ± 7.97          14.60 ± 6.73          0.84
  Duration of hypertension (years)                     12.23 ± 9.88          10.52 ± 8.22          **0.02**
  SBP \[mmHg\]                                         155.27 ± 18.92        149.84 ± 19.63        **\<0.001**
  DBP \[mmHg\]                                         84.87 ± 11.63         84.06 ± 11.42         0.36
  BMI                                                  31.3 ± 4.68           30.77 ± 5.0           0.23
  Active smokers                                       6.6%                  8.9%                  0.31
  CVD                                                  20.0%                 12.2%                 **0.007**
  Family history of CVD                                41.3%                 58.7%                 0.91
  DR                                                   37.8%                 24.6%                 **\<0.001**
  Duration of DR (years)                               3.94 ± 3.11           6.54 ± 7.03           0.23
  DNeur                                                9.1%                  6.0%                  0.38
  DF                                                   15.5%                 8.1%                  **0.03**
  S-HbA1c \[%\]^1^                                     7.98 ± 1.38           7.65 ± 1.14           **0.001**
  S-fasting glucose \[mmol/l\]                         9.03 ± 2.76           8.51 ± 2.53           **0.01**
  S-Hb \[g/l\]                                         139.39 ± 14.91        139.40 ± 12.96        0.99
  S-urea \[mmol/l\]                                    7.35 ± 3.73           6.25 ± 1.91           **\<0.001**
  S-creatinine \[*μ*mol/l\]                            93.13 ± 58.21         78.44 ± 20.15         **\<0.001**
  Male sex                                             101.57 ± 61.84^*∗*^   84.28 ± 19.94^*∗*^    **\<**0.001^**∗**^
  Female sex                                           79.7 ± 49.21^*∗∗*^    71.91 ± 18.35^*∗∗*^   **\<0.001**
  eGFR \[MDRD equation, ml/min\]                       72.6 ± 19.74          75.22 ± 15.16         0.22
  male sex                                             71.97 ± 19.45^*∗*^    77.66 ± 14.33^*∗*^    0.002^**∗**^
  female sex                                           74.31 ± 20.72^*∗∗*^   72.45 ± 15.69^*∗∗*^   0.13^*∗∗*^
  S-cystatin C \[mg/l\]                                0.95 ± 0.48           0.78 ± 0.21           **\<0.001**
  S-Total cholesterol \[mmol/l\]                       4.62 ± 1.17           4.55 ± 0.99           0.42
  S-HDL \[mmol/l\]                                     1.23 ± 0.35           1.26 ± 0.36           0.29
  S-LDL \[mmol/l\]                                     2.59 ± 0.95           2.57 ± 0.80           0.73
  S-TG \[mmol/l\]                                      2.08 ± 1.6            1.83 ± 1.24           **0.04**
  U-albumin/creatinine ratio \[g/mol\], sample no. 1   27.49 ± 55.46         1.57 ± 3.05           **\<0.001**
  U-albumin/creatinine ratio \[g/mol\], sample no. 2   23.13 ± 39.34         1.60 ± 3.67           **\<0.001**
  U-albumin/creatinine ratio \[g/mol\], sample no. 3   23.36 ± 42.49         1.62 ± 2.49           **\<0.001**

The values represent mean ± standard deviation. Bold indicates statistically significant results.

^1^The average value for hemoglobin A1c (HbA1c).

^*∗*^Comparing eGFR in men with DN and men without DN.

^*∗∗*^Comparing women with DN and women without DN.

###### 

Distribution of rs668 polymorphism genotypes and alleles in patients with diabetic nephropathy (cases) and in those without diabetic nephropathy (controls).

                  Cases (276)   Controls (375)   *p* value
  --------------- ------------- ---------------- -----------
  rs668                                           
   GG             56 (20.4)     64 (17.0)        0.3
   GC             144 (52.0)    189 (50.3)       
   CC             76 (27.6)     122 (32.7)       
                                                 
   G allele (%)   256 (46.4)    317 (42.3)       0.2
   C allele (%)   296 (53.6)    433 (57.7)       
   PHWE^†^        0.42          0.53              

PHWE^†^ = *p* values for the HWE were computed using Pearson\'s goodness-of-fit chi-square (1df).

###### 

Logistic regression analysis adjusted for different confounders (duration of hypertension, systolic blood pressure, CVD, diabetic retinopathy, diabetic foot, HbA1c, fasting glucose, urea, creatinine, cystatin C, and urine albumin/creatinine ratio) according to codominant genetic model.

  -------------------------------------------------------------------------------------------------------------------------------
  Inheritance\   Genotype    Cases (276)   Controls (375)   Unadjusted OR, 95% CI/*p* value   Adjusted OR, 95% CI/*p* ^†^ value
  model                                                                                       
  -------------- ----------- ------------- ---------------- --------------------------------- -----------------------------------
  rs668          GG          56 (20.4)     64 (17.0)        1.42 (0.89--2.24)/0.1             0.85 (0.34--2.11)/0.7

  Codominant     GC          144 (52.0)    189 (50.3)       1.23 (0.86--1.75)/0.3             1.65 (0.83--3.26)/0.9

  CC             76 (27.6)   122 (32.7)    Reference        Reference                         
  -------------------------------------------------------------------------------------------------------------------------------

*p* ^†^ values were adjusted for duration of hypertension, SBP, CVD, DR, DF, haemoglobin A~1C~, haemoglobin A1C (HbA1c), S-fasting glucose, S-urea, S-creatinine, S-cystatin, and U-albumin/creatinine ratio \[g/mol\], sample no. 1--no. 3.

Odds ratio (OR); confidence interval (CI).

###### 

The serum PECAM-1 levels in a subpopulation of 120 diabetics with DN according to different genotypes of rs668 polymorphism.

  Polymorphism   Genotype (number)           PECAM (ng/ml)               *p* value
  -------------- --------------------------- --------------------------- -----------
  rs668          GG (25)                     95.6 ± 21.7 (86.6--104.5)   0.9
  GC (61)        96.0 ± 22.5 (90.3--101.8)                               
  CC (34)        96.8 ± 20.8 (89.5--104.1)                               

Values are mean ± SD (95% confidence interval).
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